Home / Pharmaceuticals / Naloxone Market By Formulation (Parenteral, Intranasal), By End-User (Hospitals, Clinics, Emergency Medical Service (EMS), Others) - Growth, Future Prospects & Competitive Analysis, 2018 – 2026

Naloxone Market By Formulation (Parenteral, Intranasal), By End-User (Hospitals, Clinics, Emergency Medical Service (EMS), Others) - Growth, Future Prospects & Competitive Analysis, 2018 – 2026

Published: Nov 2018 | Report Code: 59436-11-18

Industry Outlook

The global naloxone market held US$ 2,602.3 Mn in 2017 and expected to grow at compound annual growth rate (CAGR) of 9.7% during the forecast period from 2018 to 2026. Naloxone is an opioid antagonist designed to rapidly reverse opioid overdose. Naloxone is able to restore normal respiration of a person whose breathing has stopped or slowed down due to opioid or heroin overdose. Currently, opioid abuse is one of the foremost cause of drug overdose and leading cause of death globally. However, it is more common in North America and Europe. The problem is paramount in the United States, where the mortality due to opioid overdose surged by 21% in 2016. The opioid crises in the U.S. is has reached epidemic phase, causing serious healthcare costs and losses to resources. The excessive need for better treatment and people suffering from opioid dependence is resulting in the growth in naloxone market in the United States. Opioid dependence is a serious concern globally, with more than 25 million people affected. The problem exists in both developed as well as developing countries, but is greatest in the Unites States. Heroin is the most abused opioid in the world apart from U.S. where opioid prescription painkillers are the largely consumed leading to dependency and overdose. All these factors act as a drivers of the global naloxone market. However, overall the price of Naloxone is rising and acting as a barrier to reduce the number of deaths caused due to opioid overdose. In the United States the effect of sky rocketing prices is being reduced with supportive insurance plans and free sale of Naloxone through community based organizations or public health programs.

Market Synopsis

Naloxone Market

Rising Awareness Related to Opioid Overdose and its Effective Treatment in Developed as well as Developing Countries

According to Penington Institute, globally an estimate of 0.19 million premature deaths caused by drugs, of which opioids account for the maximum share of drug-related deaths and that are avoidable in most cases. In January 2017, the Centre for Disease Control and Prevention (CDC) estimated that 64,070 people dies of overdoses in the 12 month period between 2016 and 2017. Thus, these statistics exhibit a clear picture of effect of opioid over dose across the globe. Government and non-government agencies across the developed and developing countries are introducing awareness campaigns to educate people about the overdose of Naloxone and treatment options. For example, Good Samaritan laws is established in the 40 states in the U.S. providing protection for people reporting overdoses in good faith. The scope of offenses are protected by immunity provision that differ state wise.

Naloxone Market

North America Dominated the Global Naloxone Market

In 2017, North America held the largest share in the global naloxone market owing wide presence of pharmaceutical giants, huge manufacturing base and favorable government initiative to curb opioid overdose crises in the region. U.S. is the leading market for Naloxone due to sharp increase in the prescription painkillers resulting in the over 10 million high-risk opioid users in the U.S. It is estimated that half this population have developed dependence and only 16% are undergoing treatment. Increasing government campaigns regarding knowledge and awareness of opioid dependence and risks have further driven the market for naloxone. Efficient reimbursement scenario and subsidized rate of the medication due to The Affordable Care Act has led to the heightened demand for naloxone. Europe emerged as the fastest growing region due to growing cases of opioid dependence, awareness and greater access to treatment.

Naloxone Market

Historical & Forecast Period

2016 – Historical Year

2017 – Base Year

2018-2026 – Forecast Period

This research report presents the analysis of each segment from 2016 to 2026 considering 2017 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segments calculated for the forecast period from 2018 to 2026.

Naloxone Market

Report Scope by Segments

Naloxone market report furnishes quantitative analysis along with its latest market trends. The market is segmented based on formulation type, end-user, and geography.

By Formulation Type (2016–2026; US$ Mn)

  • Parenteral
  • Intranasal

By End-User (2016 – 2026; Mn)

  • Hospitals
  • Clinics
  • Emergency Medical Service (EMS)
  • Others (Outpatient Retail, Online Pharmacy, etc.)

Geography Segment (2016–2026; US$ Mn)

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia Pacific (APAC)
    • China
    • Japan
    • Rest of APAC
  • Latin America (LATAM)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa (MEA)
    • GCC
    • Rest of Middle East and Africa

Market is studied in order to understand the current dynamics and future trends in the global naloxone market. The study includes market size and forecast for all considered segments presented in the report for the period from 2016 to 2026, along with respective compound annual growth rate (CAGRs) for the forecast period from 2018 to 2026, considering 2017 as the base year. The key players currently engaged in naloxone market include Hospira (Pfizer, Inc.), Mylan N.V., Kaleo, Inc., Amphastar Pharmaceuticals, Inc., Adapt Pharma, Inc., Mundipharma International Limited among others. The market players are engaged in receiving marketing authorization in North America and Europe owing greater target population. In 2016, Mylan N.V. launched naloxone hydrochloride injection in the U.S.; while Mundipharma received European Medicines Approval (EMA) for intranasal naloxone in 2017. Number of generic manufacturers are operating in the market and account for a significant share in the naloxone market.

Key questions answered in this report

  • How the global naloxone market will perform during the forecast period from 2018 to 2026?
  • What are the latest trends in the naloxone market and valuable opportunities for key players?
  • Who are the leading players in the global naloxone market?
  • Which is the leading/and fastest region in the global naloxone market?
  • What are drivers and restrains governing the global naloxone market?
  • What are regulatory scenario for naloxone in North America, Europe and Rest of the World?
  • What is the epidemiology of opioid dependence and risk associated with it to society?

Chapter 1. Preface
1.1. Report Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Primary Research
1.3.3. Phase III – Expert Panel Review
1.3.4. Assumptions
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global Naloxone Market Portraiture
2.2. Global Naloxone Market, by Formulation, 2017 (US$ Mn)
2.3. Global Naloxone Market, by End-User, 2017 (US$ Mn)
2.4. Global Naloxone Market, by Geography, 2017 (US$ Mn)

Chapter 3. Naloxone: Market Dynamics and Outlook
3.1. Market Overview
3.2. Drivers
3.2.1. Driver 1
3.2.2. Driver 2
3.3. Challenges
3.3.1. Challenge 1
3.3.2. Challenge 2
3.4. Opportunities
3.4.1. Opportunity 1
3.4.2. Opportunity 2
3.5. Naloxone Pricing Analysis (2016 – 2026)
3.6. Attractive Investment Proposition, by Geography, 2017
3.7. Competitive Analysis: Global Naloxone Market, by Key Players, 2017

Chapter 4. Global Naloxone Market, by Formulation, 2016-2026 (US$ Mn)
4.1. Overview
4.2. Parenteral
4.3. Intranasal

Chapter 5. Global Naloxone Market, by End-User, 2016-2026 (US$ Mn)
5.1. Overview
5.2. Hospitals
5.3. Clinics
5.4. Emergency Medical Service (EMS)
5.5. Others (Outpatient Retail, Online Pharmacy, etc.)

Chapter 6. Global Naloxone Market, by Geography, 2016 – 2026 (US$ Mn)
6.1. North America Naloxone Market Analysis, 2016 – 2026
6.1.1. North America Naloxone Market, by Formulation, 2016 - 2026 (US$ Mn)
6.1.2. North America Naloxone Market, by End-User, 2016 - 2026 (US$ Mn)
6.1.3. North America Naloxone Market, by Country, 2016 – 2026 (US$ Mn)
6.1.3.1. U.S.
6.1.3.2. Canada
6.2. Europe Naloxone Market Analysis, 2016 – 2026
6.2.1. Europe Naloxone Market, by Formulation, 2016 - 2026 (US$ Mn)
6.2.2. Europe Naloxone Market, by End-User, 2016 - 2026 (US$ Mn)
6.2.3. Europe Naloxone Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.2.3.1. U.K.
6.2.3.2. Germany
6.2.3.3. Rest of Europe
6.3. Asia Pacific Naloxone Market Analysis, 2016 – 2026
6.3.1. Asia Pacific Naloxone Market, by Formulation, 2016 - 2026 (US$ Mn)
6.3.2. Asia Pacific Naloxone Market, by End-User, 2016 - 2026 (US$ Mn)
6.3.3. Asia Pacific Naloxone Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.3.3.1. China
6.3.3.2. Japan
6.3.3.3. Rest of Asia Pacific
6.4. Latin America Naloxone Market Analysis, 2016 – 2026
6.4.1. Latin America Naloxone Market, by Formulation, 2016 - 2026 (US$ Mn)
6.4.2. Latin America Naloxone Market, by End-User, 2016 - 2026 (US$ Mn)
6.4.3. Latin America Naloxone Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.4.3.1. Brazil
6.4.3.2. Mexico
6.4.3.3. Rest of Latin America
6.5. Middle East & Africa Naloxone Market, 2016 – 2026
6.5.1. Middle East & Africa Naloxone Market, by Formulations, 2016 - 2026 (US$ Mn)
6.5.2. Middle East & Africa Naloxone Market, by End-User, 2016 - 2026 (US$ Mn)
6.5.3. Middle East & Africa Naloxone Market, by Region, 2016 – 2026 (US$ Mn)
6.5.3.1. GCC
6.5.3.2. Rest of Middle East & Africa

Chapter 7. Company Profiles
7.1. Mylan N.V.
7.1.1. Business Description
7.1.2. Financial Information (Subject to Data Availability)
7.1.3. Product Portfolio
7.1.4. News Coverage
7.2. Indivior Plc.
7.3. Sandoz (Novartis AG)
7.4. Adapt Pharma, Inc.
7.5. Amphastar Pharmaceuticals, Inc.
7.6. INSYS Therapeutics, Inc.
7.7. Mundipharma International Limited
7.8. Kaleo, Inc.
7.9. Kern Pharma, S.L.
7.10. Hospira (Pfizer, Inc.)
7.11. UCB Pharma

Note:

Modification in the list of company profiles or scope of the study can be incorporated on request.

FIG 1. Naloxone Market: Research Methodology
FIG 2. Naloxone: Market Segmentation
FIG 3. Global Naloxone s Market, by Formulation, 2017 (US$ Mn)
FIG 4. Global Naloxone Market, by End-User, 2017 (US$ Mn)
FIG 5. Global Naloxone Market, by Geography, 2017 (US$ Mn)
FIG 6. Attractive Investment Proposition, by Geography, 2017
FIG 7. Competitive Analysis: Global Naloxone Market, by Key Players, 2017
FIG 8. Global Parental Naloxone Formulation Market, 2016-2026 (US$ Mn)
FIG 9. Global Intranasal Naloxone Formulation Market, 2016-2026(US$ Mn)
FIG 10. Global Hospital End-User Market for Naloxone, 2016-2026(US$ Mn)
FIG 11. Global Clinics End-User Market for Naloxone, 2016-2026(US$ Mn)
FIG 12. Global Emergency Medical Service (EMS) End-User for Naloxone, 2016-2026(US$ Mn)
FIG 13. Global Other End-User Market in Naloxone, 2016-2026(US$ Mn)
FIG 14. U.S. Naloxone Market, 2016-2026 (US$ Mn)
FIG 15. Canada Naloxone Market, 2016-2026 (US$ Mn)
FIG 16. U.K. Naloxone Market, 2016-2026 (US$ Mn)
FIG 17. Germany Naloxone Market, 2016-2026 (US$ Mn)
FIG 18. Rest of Europe Naloxone Market, 2016-2026 (US$ Mn)
FIG 19. China Naloxone Market, 2016-2026 (US$ Mn)
FIG 20. Japan Naloxone Market, 2016-2026 (US$ Mn)
FIG 21. Rest of Asia Pacific Naloxone Market, 2016-2026 (US$ Mn)
FIG 22. Brazil Naloxone Market, 2016-2026 (US$ Mn)
FIG 23. Mexico Naloxone Market, 2016-2026 (US$ Mn)
FIG 24. Rest of Latin America Naloxone Market, 2016-2026 (US$ Mn)
FIG 25. GCC Naloxone Market, 2016-2026 (US$ Mn)
FIG 26. Rest of Middle East & Africa Naloxone Market, 2016-2026 (US$ Mn)

TABLE 1 Global Naloxone Market Portraiture
TABLE 2 Global Naloxone Market, by Formulation Type, 2016 – 2026 (US$ Mn)
TABLE 3 Global Naloxone Market, by End-User, 2016 – 2026 (US$ Mn)
TABLE 4 Global Naloxone Market, by Geography, 2016 – 2026 (US$ Mn)
TABLE 5 North America Naloxone Market, by Formulation Type, 2016 – 2026 (US$ Mn)
TABLE 6 North America Naloxone Market, by End-User, 2016 – 2026 (US$ Mn)
TABLE 7 North America Naloxone Market, by Country, 2016 – 2026 (US$ Mn)
TABLE 8 Europe Naloxone Market, by Formulation Type, 2016 – 2026 (US$ Mn)
TABLE 9 Europe Naloxone Market, by End-User, 2016 – 2026 (US$ Mn)
TABLE 10 Europe Naloxone Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 11 Asia Pacific Naloxone Market, by Formulation Type, 2016 – 2026 (US$ Mn)
TABLE 12 Asia Pacific Naloxone Market, by End-User, 2016 – 2026 (US$ Mn)
TABLE 13 Asia Pacific Naloxone Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 14 Latin America Naloxone Market, by Formulation Type, 2016 – 2026 (US$ Mn)
TABLE 15 Latin America Naloxone Market, by End-User, 2016 – 2026 (US$ Mn)
TABLE 16 Latin America Naloxone Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 17 Middle East & Africa Naloxone Market, by Formulation Type, 2016 – 2026 (US$ Mn)
TABLE 18 Middle East & Africa Naloxone Market, by End-User, 2016 – 2026 (US$ Mn)
TABLE 19 Middle East & Africa Naloxone Market, by Region, 2016 – 2026 (US$ Mn)
TABLE 20 Mylan N.V.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 21 Indivior Plc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 22 Sandoz (Novartis AG): Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 23 Adapt Pharma, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 24 Amphastar Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 25 INSYS Therapeutics, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 26 Mundipharma International Limited: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 27 Kaleo, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 28 Kern Pharma, S.L.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 29 Hospira (Pfizer, Inc.): Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 30 UCB Pharma: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Credence Webinars

Join Credence analysts to explore the latest IT Trends

view upcoming webinars

Our Clients